Strategic companies and private equity firms contemplate investment in OmniActive, with TA Associates reportedly planning an exit.
In a significant development for the Indian nutraceuticals industry, global private equity firms and strategic suitors are currently evaluating the acquisition of a majority stake in OmniActive Health Technologies Ltd, as TA Associates plans to exit its investment in the company.
TA Associates, the current majority stakeholder in OmniActive, had previously acquired a 54% stake in the firm. The proposed sale could reach up to $1 billion, reflecting the high interest among global investment groups.
The potential buyers for OmniActive include multiple international private equity groups and industry players within the nutraceutical, health, or FMCG sectors. While specific names of potential buyers have not been publicly disclosed, discussions are underway with both private equity investors and strategic partners.
The deal is in its early stages, with TA Associates seeking advice and exploring interest from these key investor types. Other developments in the private equity and venture capital (PE/VC) space this week include a potential exit by Bain Capital from its India portfolio, and increased M&As despite a decrease in PE/VC funding.
Interestingly, LendingKart's CEO Lunia has also stepped down, and PE firms are showing interest in Jane Street partner Nuvama. Meanwhile, YES Bank has halted its CEO search.
These developments were reported on our website, offering insights into the dynamic and evolving landscape of the Indian business sector. As the evaluation process progresses, more details about the potential buyers and the deal terms are expected to emerge.
The evaluation process for the potential acquisition of a majority stake in OmniActive Health Technologies Ltd might lead to a sale that could reach up to $1 billion, signifying high finance interest among global investment groups. The possible buyers for OmniACTIVE include multiple international private equity groups and industry players within the nutraceutical, health, or FMCG sectors, indicating substantial finance negotiations and collaborations are on the horizon.
